The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers

Dammann,; Burkhardt,; Wolf, Jason

doi:10.1046/j.1365-2036.1999.00545.x

Cited by 19 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several comparative studies [21,22,23,24,25,26] of the pharmacokinetics, potency, acid suppression, clinical ecacy, and toxicity have been performed previously and have addressed the appropriate use of PPIs in the treatment of acid-related diseases. Unfortunately, none of these clinical studies [21,22,23,24,25,26] have taken into account the genetic polymorphism of CYP2C19, a major enzyme for the metabolism of PPIs in the liver [1,2,10]. Therefore, we were prompted to assess whether the kinetic and dynamic pro®les would dier between lansoprazole and rabeprazole in light of the genetically determined CYP2C19 polymorphism.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

Ieiri

Kishimoto

Okochi

et al. 2001

European Journal of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

Ieiri

Kishimoto

Okochi

et al. 2001

European Journal of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

“…Hypergastrinemia plays a role in altering bone metabolism. Due to the irreversible binding of PPI to H + /K + -ATPase of parietal cells, the concentration of hydrogen ions secreted in the stomach is reduced, resulting in increased gastric pH [48]. The elevated pH, in turn, suppresses the secretion of somatostatin from mucosal D-cells positioned in the gastric antrum.…”

Section: Mechanism Of Bone Fractures Induced By Ppimentioning

confidence: 99%

“…Apart from histamine, hypergastrinemia is related to hyperparathyroidism [48,64,65,66,67,68]. Chickens receiving five weeks of omeprazole treatment developed hypergastrinemia, as well as hyperplasia and hypertrophy of the parathyroid glands, associated with increased parathyroid hormone (PTH) gene expression [64,65].…”

Section: Mechanism Of Bone Fractures Induced By Ppimentioning

confidence: 99%

“…In addition, rats with hypergastrinemia induced by antral exclusion also developed hyperparathyroidism and increased parathyroid gland volume and weight due to hyperplasia of the parenchymal cells [67]. However, evidence on the relationship between hypergastrinemia and hyperparathyroidism in humans is more heterogenous [48,66,69,70]. In a double-blind and two-period cross-over study by Dammann et al, 12 healthy young men were treated with oral rabeprazole (20 mg per day for 14 days), but no clinically relevant effect on T3, T4, and PTH level was observed [48].…”

Section: Mechanism Of Bone Fractures Induced By Ppimentioning

confidence: 99%

See 1 more Smart Citation

Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved

Thong

Soelaiman

Chin

2019

IJERPH

103

View full text Add to dashboard Cite

The number of patients with gastroesophageal problems taking proton pump inhibitors (PPIs) is increasing. Several studies suggested a possible association between PPIs and fracture risk, especially hip fractures, but the relationship remains contentious. This review aimed to investigate the longitudinal studies published in the last five years on the relationship between PPIs and fracture risk. The mechanism underlying this relationship was also explored. Overall, PPIs were positively associated with elevated fracture risk in multiple studies (n = 14), although some studies reported no significant relationship (n = 4). Increased gastrin production and hypochlorhydria are the two main mechanisms that affect bone remodeling, mineral absorption, and muscle strength, contributing to increased fracture risk among PPI users. As a conclusion, there is a potential relationship between PPIs and fracture risks. Therefore, patients on long-term PPI treatment should pay attention to bone health status and consider prophylaxis to decrease fracture risk.

show abstract

“…Furthermore, Sviland et al (22) reported a 35.5% decrease in the oral bioavailability of melphalan in patients pretreated with cimetidine. Therefore, drugs that induce a potent and long-lasting inhibition of gastric acid secretion [a pharmacological hallmark of rabeprazole sodium (29,30) and famotidine] would predispose a patient towards this interaction. Food intake was also reported to decrease the absorption rate of oral melphalan (31,32).…”

Section: Responsementioning

confidence: 99%

The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity

Kitazawa

Kado

Ueda

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The aim of the present study was to clarify whether gastric antisecretory drugs affect the clinical efficacy and toxicity of orally administered melphalan in patients with multiple myeloma. A total of 10 patients receiving bortezomib plus oral melphalan and prednisolone (VMP) therapy between December 2011 and November 2014 were analyzed retrospectively. The patients were divided into a control group (seven patients) and a concomitant group (three patients, who were also administered with gastric antisecretory drugs). The gastric antisecretory drugs included rabeprazole sodium (two patients) and famotidine (one patient). No significant differences between the groups were observed in either the characteristics of the patients or the VMP regimen. The levels of monoclonal protein (M protein) in the control group tended to decrease (with a VMP cycle-dependency), although they were primarily stable in the concomitant group. During the second and third VMP cycles, the levels of M protein were markedly lower in the control group compared with the concomitant group. All the patients in the control group achieved a partial response, whereas those in the concomitant group exhibited stable disease. Hematological toxicity levels were revealed to be comparable between the two groups, whereas gastrointestinal toxicity was more prevalent in the control group. In conclusion, the results of the present study suggested that the clinical efficacy of melphalan may be reduced by the co-administration of gastric antisecretory drugs. This interaction may result in decreased toxicity and clinical efficacy of melphalan.

show abstract

The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers

Abstract: Rabeprazole did not influence endocrine function in healthy young male volunteers during short-term dosing. Rabeprazole substantially increased intragastric pH over a 24 h period and significantly decreased intragastric acidity and nocturnal gastric acid secretion.

Cited by 19 publications

References 19 publications

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved

The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity

Contact Info

Product

Resources

About